Trial Profile
A prospective, open-label study to evaluate the lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2016
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 04 Feb 2016 New trial record